Posted inClinical Updates Dermatology
Brepocitinib Shows Promising Efficacy and Safety in Cutaneous Sarcoidosis: Results from a Phase 2 Randomized Clinical Trial
Brepocitinib, a selective TYK2/JAK1 inhibitor, demonstrated significant, dose-dependent efficacy and safety in adults with cutaneous sarcoidosis in a 16-week phase 2 randomized trial, representing a potential new targeted therapy for this challenging skin condition.
